Woman Gets 5-Year Drug Import Ban, Ghosts Her Own Hearing
Published Date: 11/25/2025
Notice
Summary
Nicole Shelby Randall is officially banned for 5 years from importing any drugs into the U.S. because she was convicted of bringing in a bad drug that broke federal law. She didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on November 25, 2025. She can apply to end the ban anytime, but must follow special rules to keep her info private.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Five‑Year Import Ban for Nicole Randall
Nicole Shelby Randall is debarred for 5 years from importing or offering for import any drug into the United States, effective November 25, 2025. The debarment follows her January 22, 2025 felony conviction for introducing an adulterated drug into interstate commerce, and FDA states that importing drugs by, with the assistance of, or at the direction of Ms. Randall is a prohibited act.
Right to Apply and Public Filing Rules
Ms. Randall (or anyone seeking termination of debarment) may apply to end the debarment at any time under section 306(d)(1). Applications submitted electronically to https://www.regulations.gov will be posted publicly unchanged; to keep information confidential you must submit a written/paper application with two copies (one marked confidential and one redacted) to the Dockets Management Staff as described in the order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-21074 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on December 19, 2025, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info of applicants. Researchers waiting on funding decisions should note this date, but no new costs or changes to the process are announced.
Next: 2025-21076 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 6, 2026, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info. Scientists and researchers applying for grants should note this date, but no new costs or changes affect the public.